Anat Hakim
Known title: SVP, GC & SecretaryCIK: 0001685556
Associated companies
Transaction History
| LLY | ▼ Sell | Open Market | 5,000 | $6.0M | 8/7/2026 | View on chart |
| LLY | ▲ Buy | Grant | 8,278 | $8.6M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 6,700 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,953 | $3.1M | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Gift | 17,875 | $0 | 5/2/2025 | View on chart |
| LLY | ▲ Buy | Grant | 10,321 | $9.0M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,904 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 2,166 | $1.8M | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Gift | 14,700 | $0 | 8/12/2024 | View on chart |
| LLY | ▲ Buy | Grant | 5,815 | $4.3M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 4,442 | $0 | 2/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,967 | $1.3M | 2/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 9,072 | $3.1M | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 7,646 | $0 | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 3,393 | $1.2M | 2/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 3,500 | $875K | 3/1/2022 | View on chart |
| LLY | ▲ Buy | Option Exercise | 7,929 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.